Sandoz announces further progress on its biosimilar

ROSALIA study met primary endpoints, confirming proposed biosimilar denosumab matches reference product in terms of pharmacokinetics, pharmacodynamics,...

Related Keywords

United States ,Florian Bieber ,Exchange Commission ,Global Head Of Development ,European Medicines Agency ,Drug Administration ,Novartis ,Global Head ,Swiss Stock Exchange Novn ,Novartis Pharma Ag ,Media Release ,Osteoporosis ,